Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research Report) and Unicycive Therapeutics (UNCY – Research Report) with bullish sentiments.

Perspective Therapeutics (CATX)

JonesTrading analyst Justin Walsh reiterated a Buy rating on Perspective Therapeutics today and set a price target of $2.20. The company’s shares closed last Wednesday at $1.63, close to its 52-week high of $1.90.

According to TipRanks.com, Walsh is a 3-star analyst with an average return of 3.9% and a 39.7% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Fusion Pharmaceuticals, and TriSalus Life Sciences.

Currently, the analyst consensus on Perspective Therapeutics is a Strong Buy with an average price target of $2.16, a 19.3% upside from current levels. In a report issued on May 9, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock.

See the top stocks recommended by analysts >>

Unicycive Therapeutics (UNCY)

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Unicycive Therapeutics yesterday and set a price target of $4.00. The company’s shares closed last Wednesday at $1.08.

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -16.2% and a 29.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lipella Pharmaceuticals, Inc., SELLAS Life Sciences Group, and Actinium Pharmaceuticals.

Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.88, implying a 439.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CATX:

• Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
• Perspective Therapeutics initiated with an Outperform at RBC Capital
• Shopify upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
• Perspective Therapeutics initiated with an Overweight at Cantor Fitzgerald
• Perspective Therapeutics to Participate at Upcoming May Investor Conferences